Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-Making in Relation to New Cancer Drugs

Rajabali Daroudi, M. Mirzania, K. Zendehdel
{"title":"Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-Making in Relation to New Cancer Drugs","authors":"Rajabali Daroudi, M. Mirzania, K. Zendehdel","doi":"10.15171/ijhpm.2015.186","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nAlthough medical oncologists can have an important role in controlling the cost of cancer treatment, there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their treatment recommendations, especially in low- and middle-income countries (LMICs). In this study, we assessed the attitude of Iranian medical oncologists toward some economic aspects of new cancer drugs.\n\n\nMETHODS\nWe translated a questionnaire that was used in similar studies in the United States and Canada into Persian and modified it according to the local setting in Iran. The face and content validity of the questionnaire were assessed by oncologists before being used in the survey. We distributed the questionnaire and collected the data from 80 oncologists who participated in the 13th Annual Congress of the Iranian Society of Medical Oncology and Hematology (ISMOH).\n\n\nRESULTS\nFifty-two oncologists participated in our study (a response rate of 65%). The majority of oncologists stated that drug costs and patient out-of-pocket (OOP) costs influence their treatment recommendations (92% and 94%, respectively). Most oncologists (70%) felt that they are ready enough to use cost-effectiveness information in their treatment decisions, and 74% believed that patients should only have access to cancer treatments that are cost-effective. Most oncologists agree that the government should have control over drug prices, and more use of cost-effectiveness data is required for decision-making about cancer drug coverage. Ninety-one percent of oncologists said that they always or frequently discuss cancer treatment costs with their patients. Oncologists believed that academic groups (research centers and scientific societies) (81%) and the Ministry of Health (MoH) (43%) are the most eligible groups for determining whether a drug provides good value.\n\n\nCONCLUSION\nIranian medical oncologists are ready to participate in the health technology assessment and priority-setting process. This situation creates a unique opportunity for the government to rely on scientific societies and find an appropriate solution for the improvement of patients' access to high-quality care.","PeriodicalId":441294,"journal":{"name":"MedRN: Other Oncology (Topic)","volume":"12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2015-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedRN: Other Oncology (Topic)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15171/ijhpm.2015.186","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

BACKGROUND Although medical oncologists can have an important role in controlling the cost of cancer treatment, there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their treatment recommendations, especially in low- and middle-income countries (LMICs). In this study, we assessed the attitude of Iranian medical oncologists toward some economic aspects of new cancer drugs. METHODS We translated a questionnaire that was used in similar studies in the United States and Canada into Persian and modified it according to the local setting in Iran. The face and content validity of the questionnaire were assessed by oncologists before being used in the survey. We distributed the questionnaire and collected the data from 80 oncologists who participated in the 13th Annual Congress of the Iranian Society of Medical Oncology and Hematology (ISMOH). RESULTS Fifty-two oncologists participated in our study (a response rate of 65%). The majority of oncologists stated that drug costs and patient out-of-pocket (OOP) costs influence their treatment recommendations (92% and 94%, respectively). Most oncologists (70%) felt that they are ready enough to use cost-effectiveness information in their treatment decisions, and 74% believed that patients should only have access to cancer treatments that are cost-effective. Most oncologists agree that the government should have control over drug prices, and more use of cost-effectiveness data is required for decision-making about cancer drug coverage. Ninety-one percent of oncologists said that they always or frequently discuss cancer treatment costs with their patients. Oncologists believed that academic groups (research centers and scientific societies) (81%) and the Ministry of Health (MoH) (43%) are the most eligible groups for determining whether a drug provides good value. CONCLUSION Iranian medical oncologists are ready to participate in the health technology assessment and priority-setting process. This situation creates a unique opportunity for the government to rely on scientific societies and find an appropriate solution for the improvement of patients' access to high-quality care.
伊朗医学肿瘤学家对经济方面的态度,以及与新的癌症药物有关的政策制定
背景:尽管肿瘤学家在控制癌症治疗费用方面可以发挥重要作用,但关于他们对癌症治疗费用的态度以及费用对其治疗建议的影响的信息很少,特别是在低收入和中等收入国家(LMICs)。在这项研究中,我们评估了伊朗医学肿瘤学家对新的癌症药物的一些经济方面的态度。方法将美国和加拿大类似研究中使用的问卷翻译成波斯语,并根据伊朗当地情况进行修改。问卷的表面效度和内容效度在被用于调查前由肿瘤学家进行评估。我们向参加第13届伊朗肿瘤和血液学医学学会(ISMOH)年会的80位肿瘤学家分发了问卷并收集了数据。结果52名肿瘤学家参与了我们的研究,有效率为65%。大多数肿瘤学家表示,药物成本和患者自费(OOP)成本影响他们的治疗建议(分别为92%和94%)。大多数肿瘤学家(70%)认为他们已经准备好在他们的治疗决策中使用成本效益信息,74%的人认为患者应该只获得具有成本效益的癌症治疗。大多数肿瘤学家都认为,政府应该控制药品价格,在制定癌症药物覆盖范围的决策时,需要更多地使用成本效益数据。91%的肿瘤学家表示,他们总是或经常与患者讨论癌症治疗费用。肿瘤学家认为,学术团体(研究中心和科学学会)(81%)和卫生部(43%)是确定一种药物是否具有良好价值的最有资格的群体。结论伊朗内科肿瘤学家已准备好参与卫生技术评估和重点确定过程。这种情况为政府提供了一个独特的机会,可以依靠科学协会,找到适当的解决方案,改善患者获得高质量护理的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书